Discovery Life Sciences

2024 has been a pivotal year for biopharma, marked by both challenges and remarkable progress. Milestones like CAR-T therapies gaining approvals for earlier-line cancer treatments and promising antibody-drug conjugate candidates poised for approval in the new year, set the stage for exciting developments in the coming year. As we gear up for 2025, let’s take a moment to reflect on some of Discovery’s highlights from this year.?

In honor of Women’s History Month, Discovery is spotlighting five extraordinary women scientists who have shattered gender barriers and reshaped the course of science. Their groundbreaking work has deepened our understanding of disease, fueled medical breakthroughs, and transformed lives—driving real change and inspiring future generations: Jane Cooke Wright (1919 – 2013)?? Renowned cancer researcher best known for her pioneering work in chemotherapy. Dr. Wright and her team were the first to identify methotrexate, one of the foundational chemotherapy drugs, to treat solid tumors, including leukemia, Hodgkin’s disease, lymphosarcoma, melanoma, breast cancer, and prostate cancer.?? Irene Uchida? A Canadian cytogeneticist whose research helped establish the link between prenatal X-ray exposure and an increased risk of having babies with Down syndrome. Dr. Uchida’s work led to the creation of Canada’s first cytogenetics program and the development of a diagnostic blood test to detect chromosomal abnormalities like trisomy 18 in infants. Katalin Karikó? Dr. Karikó’s research in mRNA technology laid the foundation for the COVID-19 vaccine, which turned the tide in the battle against the SARS-CoV-2 virus. Her work has opened new possibilities for developing mRNA-based therapies for other diseases. Jennifer Doudna & Emmanuelle Charpentier? Awarded the 2020 Nobel Prize in Chemistry for their discovery of the CRISPR/Cas9 gene editing technology, this scientific duo has revolutionized genetic research, enabling precise DNA modifications that are leading to advancements in gene therapy, agriculture, and disease prevention.? #WomensHistoryMonth #WomenInSTEM?

We are excited to showcase our recent scientific works at Precision Med Tri-Con 2025. Look out for our luncheon presentation led by Dr. Shawn Fahl:? ? Title: Biorepository to Breakthroughs: Accelerating Development with Spatial and Transcriptomic Analyses on March 11, 2025, 12:25 PM – 12:55 PM (Spatial Biology and Single-Cell Multiomics Program).? ?? Attend the poster presentation titled Cell-Free DNA and Beyond: A Comprehensive Evaluation of Liquid Biopsy Workflows Across in a Global Clinical Biorepository. Schedule a meeting with our team today: https://lnkd.in/gV7rKQEs? #TRICON #TRICON2025?

Cell therapy’s focus is expanding beyond cancer in 2025 with increasing interest in applying CAR-T and T cell engagers (TCEs) to autoimmune diseases like lupus and multiple sclerosis. Read more about how this shift is changing the biopharma landscape:? https://lnkd.in/ee9qpHKG? At Discovery, we support the evolving CGT industry with high-quality starting cellular materials that help drive innovation from research to commercialization.

We are excited to announce the official launch of our tumoroid cell lines at the upcoming Precision Med Tri-Con 2025, from March 11-13 in San Diego.? Read full press release: https://lnkd.in/e55QVkCg “Our tumoroid cell lines are a transformative tool that will eliminate major barriers to oncology research, giving scientists a powerful, predictive tool to identify life-changing therapies faster,” said McLean Collins, Discovery’s president of Biospecimens Products & Services.“This product also represents Discovery’s continued commitment to driving innovation in cancer research and complements our cell biology offerings in CFC and ADC assays along with our 10X single cell portfolio." Our strategic investments in advanced technologies, such as tumoroids and AI-powered pathology workflow, empower our customers with actionable, quantitative insights. #tumoroids #cancerorganoids #tricon2025??

The FDA approved a novel TROP2-directed antibody-drug conjugate (ADC) drug for use in patients with HR-positive, HER2-negative breast cancer: https://lnkd.in/gWUEPCK9 Developed by AstraZeneca and Daiichi Sankyo, Datroway (datopotamab deruxtecan) reduced the risk of disease progression or death by 37% compared to chemotherapy, offering new treatment options for metastatic breast cancer patients with the potential to improve health outcomes. #FDAApproval #ADC #BreastCancer??

We look forward to seeing you at Booth 9 during Tri-Con 2025 from March 11-13!?Stop by the booth to learn more about our biospecimen solutions, including our new tumoroid products and AI-powered pathology analysis capabilities.?? Schedule a private meeting with our team today: https://lnkd.in/gV7rKQEs Shawn Fahl, Meredith Osborn MS, Dan Searson, Andy L. Chiang, T. Scott Reid #PrecisionMedicine #TRICON2025

Read the newest blog on why CAR-NK therapies are a promising alternative to CAR-T cell therapies for cancer treatment!

Join the webinar on Wednesday, March 5 at 11:00 AM ET as we discuss the cutting-edge 3D tumor models and their potential to accelerate cancer research and development. Register Today! https://lnkd.in/epuspWpt Title: Considerations in Tissue Acquisition and Characterization for the Development of Long-Term Tumoroid Models? DATE: Wednesday, March 5, 2025, 11:00 am ET Speakers: Shawn Fahl, VP Lab Operations, Cell Services & R&D, Biospecimens and Philip McCauley, Product Manager.?

With the landmark approvals of BCMA-targeted CAR-T therapies, CARVYKTI? and Abecma?, patients with multiple myeloma now have more effective treatment options—offering the potential for longer survival and for the first time, the possibility of a cure: https://lnkd.in/eKBYtjdi? Once considered incurable, multiple myeloma is now being redefined, thanks to the relentless efforts of researchers worldwide. Advancements like CAR-T therapies are transforming the treatment landscape, offering new hope for patients and their families. #celltherapy #multiplemyeloma?